Embecta Corp./EMBC

$10.88

1.49%
-
1D1W1MYTD1YMAX

About Embecta Corp.

Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The Company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.

Ticker

EMBC

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Devdatt Kurdikar

Employees

2,200

Headquarters

Parsippany, United States

Embecta Corp. Metrics

BasicAdvanced
$611.49M
Market cap
11.06
P/E ratio
$0.96
EPS
-
Beta
$0.60
Dividend rate
5.65%
Dividend yield
$611.49M
$32.00
$9.93
430.35K
$0.60
2.203
1.746
62.21%
49.242
1.67%
4.58%
6.44%
11.065
0.545
5.65%
5.65%
0.58%
-65.06%
1.06%
-45.18%

What the Analysts think about Embecta Corp.

Analyst Ratings

Majority rating from 4 analysts.
Hold

Price Targets

Average projection from 2 analysts.
51.65% upside
High $17.00
Low $16.00
$10.88
Current price
$16.50
Average price target

Embecta Corp. Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
7.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$277.3M
-1.63%
Net income
$20.1M
235%
Profit margin
7.24%
241.51%

Embecta Corp. Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 34.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.75
$0.69
$0.59
$0.61
-
Expected
$0.49
$0.46
$0.40
$0.46
$0.40
Surprise
54.11%
50%
48.43%
34.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Embecta Corp. stock?

Embecta Corp. (EMBC) has a market cap of $611.49M as of April 24, 2024.

What is the P/E ratio for Embecta Corp. stock?

The price to earnings (P/E) ratio for Embecta Corp. (EMBC) stock is 11.06 as of April 24, 2024.

Does Embecta Corp. stock pay dividends?

Yes, the Embecta Corp. (EMBC) stock pays dividends to shareholders. As of April 24, 2024, the dividend rate is $0.6 and the yield is 5.65%. Embecta Corp. has a payout ratio of 62.21% on a trailing twelve-month basis.

When is the next Embecta Corp. dividend payment date?

The next Embecta Corp. (EMBC) dividend payment date is unconfirmed.

What is the beta indicator for Embecta Corp.?

Embecta Corp. (EMBC) does not currently have a Beta indicator.

What is the Embecta Corp. stock price target?

The target price for Embecta Corp. (EMBC) stock is $16.5, which is 51.65% above the current price of $10.88. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Embecta Corp. stock

Buy or sell Embecta Corp. stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing